33 Atopic Dermatitis Clinical Trials in Detroit, MI (2026)

Q: How do I join a clinical trial in Detroit?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Detroit research site will contact you.

Recruiting Atopic Dermatitis Studies in Detroit

NCT07070232Recruiting

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in particip...

Detroit, MIPHASE11,438 participantsBioNTech SE

View Study Details

NCT05719558Recruiting

A Study of ASP1002 in Adults for Treatment of Solid Tumors

The main aims of this study are: * To check the safety of ASP1002 in people with certain solid tumors. * To check if the people can tolerate ASP1002. * To find a suitable dose of ASP1002. This study ...

Detroit, MIPHASE1798 participantsAstellas Pharma Global Development, Inc.

View Study Details

NCT06586515Recruiting

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-m...

Detroit, MIPHASE1630 participantsEli Lilly and Company

View Study Details

NCT06859762Recruiting

A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors

A Phase 1 First-in-Human study of YL217 in Patients with Advanced Solid Tumors...

Detroit, MIPHASE1630 participantsMediLink Therapeutics (Suzhou) Co., Ltd.

View Study Details

NCT05875168Recruiting

First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors....

Detroit, MIPHASE1590 participantsDaiichi Sankyo

View Study Details

NCT03526835Recruiting

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC...

Detroit, MIPHASE1560 participantsMerus N.V.

View Study Details

NCT05584670Recruiting

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

This is a Phase 1/2, open label, multiple cohort study to assess the safety and preliminary efficacy of SAR445877 as a monotherapy or in combination with other anticancer therapies for participants ag...

Detroit, MIPHASE1542 participantsSanofi

View Study Details

NCT06384807Recruiting

A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors....

Detroit, MIPHASE1500 participantsBiohaven Therapeutics Ltd.

View Study Details

NCT05410145Recruiting

A Study of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

This is a first-in-human (FIH), multicenter, open-label, dose-escalation, and dose-expansion Phase 1/2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and prel...

Detroit, MIPHASE1442 participantsD3 Bio (Wuxi) Co., Ltd

View Study Details

NCT05592626Recruiting

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with ad...

Detroit, MIPHASE1366 participantsMarengo Therapeutics, Inc.

View Study Details

NCT06241456Recruiting

FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

This is a phase 1 study designed to evaluate the safety, tolerability, and antitumor activity of FT825 (also known as ONO-8250) with or without monoclonal antibody therapy following chemotherapy in pa...

Detroit, MIPHASE1351 participantsFate Therapeutics

View Study Details

NCT07003425Recruiting

A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an A...

Detroit, MIPHASE2350 participantsApogee Therapeutics, Inc.

View Study Details

NCT05434234Recruiting

A Study of YL201 in Patients With Advanced Solid Tumors

This is a phase 1, multicenter, nonrandomized, open-label, first-in-human study of YL201 conducted in China and the United States. The study will include 2 parts: a dose escalation part (Part 1) follo...

Detroit, MIPHASE1312 participantsMediLink Therapeutics (Suzhou) Co., Ltd.

View Study Details

NCT06724016Recruiting

Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors

This is a First-in-Human, Phase 1, Dose-Escalation and Dose-Expansion study of HM16390, as a single agent and in combination with pembrolizumab to assess safety, tolerability, MTD, RP2D, PK, and effic...

Detroit, MIPHASE1292 participantsHanmi Pharmaceutical Company Limited

View Study Details

NCT07335497Recruiting

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

The purpose of this study is to determine the safety and tolerability of monotherapy CR-001 and identify the maximum tolerated dose (MTD), and/or optimal biologic dose and Recommended Phase 2 Dose(s) ...

Detroit, MIPHASE1290 participantsCrescent Biopharma, Inc.

View Study Details

NCT06385080Recruiting

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Recurrent/Metastatic Head and Neck Cancer

The purpose of this study is to determine safety and preliminary efficacy of amivantamab monotherapy, amivantamab in addition to pembrolizumab, amivantamab in addition to paclitaxel and amivantamab in...

Detroit, MIPHASE1287 participantsJanssen Research & Development, LLC

View Study Details

NCT07205718Recruiting

A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors

TAK-188 is a new medicine that targets a protein called CCR8, which is found on the surface of certain cells (Tregs) inside tumors. These cells can weaken the body's ability to fight cancer. TAK-188 m...

Detroit, MIPHASE1273 participantsTakeda

View Study Details

NCT07186842Recruiting

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

The main goal of this study is to evaluate the safety of BNT329 and to identify the best dose of BNT329. This will be done by measuring the number of side effects that participants experience and how ...

Detroit, MIPHASE1245 participantsBioNTech SE

View Study Details

NCT06799065Recruiting

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and pr...

Detroit, MIPHASE1218 participantsAccent Therapeutics

View Study Details

NCT06521554Recruiting

A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)

Phase 1a/1b dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-330, determine the recommended Phase 2 dose (RP2D), and evaluate the antitumor activity in parti...

Detroit, MIPHASE1200 participantsNuvalent Inc.

View Study Details

NCT07488676Recruiting

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors. GEJ is where the ...

Detroit, MIPHASE1150 participantsAstellas Pharma Global Development, Inc.

View Study Details

NCT06974110Recruiting

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clini...

Detroit, MIPHASE1132 participantsMOMA Therapeutics

View Study Details

NCT06769698Recruiting

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab compared against cemiplimab combined with placebo (a placebo looks ...

Detroit, MIPHASE2120 participantsRegeneron Pharmaceuticals

View Study Details

NCT07130903Recruiting

Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer

The goal of this clinical trial is to learn if adding amplitude-modulated radiofrequency electromagnetic fields (AM RF EMF) to Fruquintinib in metastatic colorectal cancer that has not responded to ot...

Detroit, MIPHASE2102 participantsBarbara Ann Karmanos Cancer Institute

View Study Details

NCT05490472Recruiting

JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors....

Detroit, MIPHASE1102 participantsJacobio Pharmaceuticals Co., Ltd.

View Study Details

NCT07244263Recruiting

A Study of Zasocitinib in Adults With Hidradenitis Suppurativa

Hidradenitis Suppurativa (HS) is a skin condition that causes deep, painful bumps on the skin. These bumps usually appear in an area where the skin rubs together. They start as small bumps but may bec...

Detroit, MIPHASE290 participantsTakeda

View Study Details

NCT05038150Recruiting

Study of SGN1 in Patients With Advanced Solid Tumor

Objectives:To assess the safety and tolerability followed by a dose expansion study to characterize safety, and preliminary efficacy of SGN1 in participants with refractory solid tumors. Study Ration...

Detroit, MIPHASE170 participantsGuangzhou Sinogen Pharmaceutical Co., Ltd

View Study Details

NCT05886920Recruiting

A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations

This first-in-human (FIH) study aims to assess the safety, tolerability, pharmacokinetics, and recommended phase 2 dose (RP2D) of D3S-002 given orally daily for 21-day cycles in adult subjects with ad...

Detroit, MIPHASE167 participantsD3 Bio (Wuxi) Co., Ltd

View Study Details

NCT06307795Recruiting

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in particip...

Detroit, MIPHASE163 participantsAvistone Biotechnology Co., Ltd.

View Study Details

NCT04196257Recruiting

BP1001-A in Patients With Advanced or Recurrent Solid Tumors

This is a phase I, open-label, study of BP1001-A in participants with advanced or recurrent solid tumors. The dose escalation phase will determine the safety and the maximum tolerated dose (MTD) or ma...

Detroit, MIPHASE150 participantsBio-Path Holdings, Inc.

View Study Details

NCT06576115Recruiting

Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer

The goal of this study is to learn if the combination of nab-paclitaxel, gemcitabine and an Amplitude-Modulated Radiofrequency Electromagnetic Fields device (Therabionic P1) is safe and effective for ...

Detroit, MIPHASE230 participantsBarbara Ann Karmanos Cancer Institute

View Study Details

NCT06673017Recruiting

PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)

This is a multi-center, non-randomized, single-arm, open-label, phase Ib, dose escalation/dose expansion study of PTM-101 when combined with neoadjuvant chemotherapy for the treatment of treatment-naï...

Detroit, MIPHASE126 participantsPanTher Therapeutics

View Study Details

NCT07036133Recruiting

Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment

This purpose of this study is to help to evaluate the pharmacokinetic (PK) profile of pralatrexate when administered to patients with various degrees of hepatic impairment and to evaluate the safety a...

Detroit, MIPHASE124 participantsAcrotech Biopharma Inc.

View Study Details

About Atopic Dermatitis Clinical Trials in Detroit

Atopic dermatitis (eczema) is a chronic inflammatory skin condition causing itchy, red, and dry skin. It is the most common form of eczema, often beginning in childhood. Treatment includes moisturizers, topical corticosteroids, immunomodulators, and newer biologics like dupilumab.

There are currently 33 atopic dermatitis clinical trials recruiting participants in Detroit, MI. These studies are seeking a combined 10,340 participants. Research is being sponsored by BioNTech SE, Astellas Pharma Global Development, Inc., Eli Lilly and Company and 24 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Atopic Dermatitis Clinical Trials in Detroit — FAQ

Are there atopic dermatitis clinical trials in Detroit?

Yes, there are 33 atopic dermatitis clinical trials currently recruiting in Detroit, MI. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Detroit?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Detroit research site will contact you about next steps.

Are clinical trials in Detroit free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Detroit studies also compensate for your time and travel.

What atopic dermatitis treatments are being tested?

The 33 active trials in Detroit are testing new therapies including novel drugs, biologics, and treatment approaches for atopic dermatitis.

Data updated October 16, 2026 from ClinicalTrials.gov